Entering text into the input field will update the search result below

Ligand Pharma, iRhythm Tech new shorts at Lakeland Capital

  • Anthony Bozza sees more than 50% downside in Ligand Pharmaceuticals (LGND -3.1%), according to his fund's Q1 letter. The market, he says, overvalues the company's pipeline.
  • iRhythm (IRTC -7%) has nearly 70% downside, says Bozza, noting a fancy valuation in the face of continuing losses and looming competitive threats.
  • Source: Bloomberg

Recommended For You

About LGND Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LGND--
Ligand Pharmaceuticals Incorporated